Michael Chang points out that Taiwan's biotech industry not only lacks capital, it also lacks drug-development personnel. Drug development requires people able to evaluate drug safety, design clinical trials, manage chemistry manufacturing and controls (CMC), etc.
張念原坦言，資金之外，國內生技產業也欠缺「藥物發展」的人才──他們必須懂得如何做藥物安全性評估、臨床試驗設計、化學製造管制（CMC）等等。